---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031249"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:08:32.203228+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Omeros Q3 net loss $37.8M; discontinues IgA nephropathy trial, targets narsoplimab BLA in mid-2024

## Summary
- Net loss of $37.8M ($0.60/sh) vs $17.5M prior year; continuing ops loss $51.7M, down from $54.8M.
- OMIDRIA royalties $10.0M on $33.3M US sales (down from $16.5M) due to royalty rate drop to 30%.
- $310.3M cash as of Sept 30; expects to repay $95M convertible notes due Nov 15, 2023.
- Phase 3 ARTEMIS-IGAN trial for IgA nephropathy discontinued after interim analysis missed primary endpoint.
- BLA resubmission for narsoplimab in TA-TMA on track for FDA decision mid-2024; OMS906 Phase 2 PNH data pending.

## SEC filing metadata
- accession: 0001437749-23-031249
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774923031249/0001437749-23-031249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774923031249/omer20230905_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031249
- JSON: https://secwatch.observer/filing/0001437749-23-031249.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031249.txt

## Key facts
- Earnings Releases
  OMEROS CORP reported third quarter ended September 30, 2023 results: net income Net loss was $37.8 million for the quarter ended September 30, 2023, or $0.60 per share, EPS $0.60 per share.
  - Period: third quarter ended September 30, 2023
  - Net income: Net loss was $37.8 million for the quarter ended September 30, 2023, or $0.60 per share
  - EPS: $0.60 per share
  - Result: reported results
  source text: Net loss was $37.8 million for the quarter ended September 30, 2023, or $0.60 per share, compared to a net loss in the prior year quarter of $17.5 million, or $0.28 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285819/000143774923031249/0001437749-23-031249-index.htm
- Earnings Releases
  OMEROS CORP reported nine months ended September 30, 2023 results: net income net loss was $108.8 million, or $1.73 per share, EPS $1.73 per share.
  - Period: nine months ended September 30, 2023
  - Net income: net loss was $108.8 million, or $1.73 per share
  - EPS: $1.73 per share
  - Result: reported results
  source text: For the nine months ended September 30, 2023, our net loss was $108.8 million, or $1.73 per share, compared to a net loss of $81.3 million, or $1.30 per share, in the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285819/000143774923031249/0001437749-23-031249-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.